Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person In the presence of the proteasome inhibitor MG132, polyubiqu...

Class:IdSummation:3640831
_displayNameIn the presence of the proteasome inhibitor MG132, polyubiqu...
_timestamp2013-05-29 20:36:48
created[InstanceEdit:3640832] Rothfels, K, 2013-05-29
textIn the presence of the proteasome inhibitor MG132, polyubiquitinated forms of AXIN accumulate (Huang et al, 2009; Zhang et al, 2011; Callow et al, 2011). This effect is abrogated by co-treatment of cells with both MG132 and inhibitors of tankyrase activity, suggesting that both PARSylation and ubiquitination are required for AXIN degradation (Huang et al, 2009).
(summation)[BlackBoxEvent:3640874] Ub-RibC-AXIN is degraded by the proteasome [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by In the presence of the proteasome inhibitor MG132, polyubiqu... (3640831)